NEW YORK–(BUSINESS WIRE) December 20, 2024 — Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux® ) and mFOLFOX6…Original Article
U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
